1 Viral kinetics of sequential SARS-CoV-2 infections

- Stephen M Kissler¹, James A Hay², Joseph R Fauver³, Christina Mack⁴, Caroline G Tai⁴, Deverick J An derson⁵, David D Ho⁶, Nathan D Grubaugh⁷, Yonatan H Grad¹
 - dereent,
 - ¹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston MA USA
- ² Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford,
 UK
- ¹⁰ ³ Department of Epidemiology, University of Nebraska Medical Center, Omaha NE USA
- 11 4 IQVIA, Durham NC USA
- ⁵ Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham NC USA
- ⁶ Vagelos College of Physicians and Surgeons, Columbia University, New York NY USA
- ⁷ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven CT USA
- 15 16

2

5

6 7

Abstract. The impact of a prior SARS-CoV-2 infection on the progression of subsequent infec-17 18 tions has been unclear. Using a convenience sample of 94,812 longitudinal RT-qPCR measurements from anterior nares and oropharyngeal swabs, we compared the SARS-CoV-2 viral kinetics 19 of first vs. second infections, adjusting for viral variant, vaccination status, and age. Relative to 20 first infections, second infections usually featured a lower peak viral concentration and faster 21 clearance time, especially in individuals who received a vaccine dose between their first and sec-22 ond infection. Furthermore, a person's relative (rank-order) viral clearance time, compared to oth-23 ers infected with the same variant, was similar across first and second infections; that is, individ-24 uals who had a relatively fast clearance time in their first infection tended to also have a relatively 25 fast clearance time in their second infection. These findings provide evidence that, like vaccina-26 tion, immunity from a prior SARS-CoV-2 infection shortens the duration of subsequent acute 27 SARS-CoV-2 infections principally by reducing viral clearance time. Additionally, there appears 28 to be an inherent element of the immune response, or some other host factor, that shapes a 29 person's relative ability to clear SARS-CoV-2 infection that persists across sequential infections. 30 31

32 **Key words.** Viral kinetics; SARS-CoV-2; reinfection; clearance

Introduction. 33

34

An estimated 65% of the US population had at least two SARS-CoV-2 infections by November 35 2022, but the impact of prior infection on disease course in subsequent infections has been de-36 bated.1 Some evidence indicates SARS-CoV-2 infection provides a temporary reduction in re-37 infection risk² and a durable reduction in the risk of COVID-19-related hospitalization and death,³ 38 while a handful of studies suggest that an initial SARS-CoV-2 infection may limit recovery from 39 COVID-19 infections.⁴ These contrasting findings may result from biases that can arise in popu-40 lation-level studies when differences in exposure history, vaccination status, and comorbidities 41 are not fully accounted for. Controlling for such factors is a major challenge given geographically 42 and temporally heterogeneous interventions, whereas examining the dynamics of SARS-CoV-2 43 44 infections at the individual level can facilitate adjusting for these biases.

45

Reverse transcription quantitative PCR (RT-qPCR) conducted from clinical samples collected at 46 multiple time points offer an objective, quantitative metric of SARS-CoV-2 kinetics and can inform 47 48 on key aspects of immune response and clinical progress. Such data have been used to specify 49 how vaccination history, antibody titer and viral lineage together shape SARS-CoV-2 proliferation and clearance during an acute infection.⁵ which in turn can inform the clinical management of 50 COVID-19⁶ and help interpret epidemiological trends.⁷ Viral kinetics therefore offer a promising 51 52 metric for clarifying the impact of an initial SARS-CoV-2 infection on subsequent infections and for translating those findings into medical and public health guidance. 53 54

The impact of vaccination and variant on SARS-CoV-2 viral kinetics have been well described 55 elsewhere.^{8–13} Infections with Delta lineages feature a higher peak viral concentration than Alpha 56 or Omicron infections, and vaccination speeds up the clearance of SARS-CoV-2 across line-57 ages.¹¹ However, the impact of SARS-CoV-2 infection-conferred immunity on peak viral concen-58 tration, viral proliferation, and viral clearance in subsequent infections is less well characterized. 59 Furthermore, it has been unclear to what extent attributes of SARS-CoV-2 kinetics, such as peak 60 viral load or clearance rate, persist across an individual's successive infections. 61

62

Here, we collected and analyzed 94.812 SARS-CoV-2 RT-gPCR viral concentration measure-63 ments taken from longitudinal clinical samples in players, staff, and affiliates of the National Bas-64 ketball Association (NBA) between March 11th, 2020, and July 28th, 2022. For the subset of indi-65 viduals who were infected twice during the study period, we measured changes in viral kinetics 66 between first and second infections and determined the extent to which viral kinetic features per-67 sisted across infections. 68

- Methods. 70
- 71

69

Study design. Between March 11th, 2020, and July 28th, 2022, the NBA conducted regular surveil-72 lance for SARS-CoV-2 infection among players, staff, and affiliates as part of an occupational 73

health program. This included frequent viral testing (often daily during high community COVID-19 74

prevalence) using a variety of platforms, but primarily via nucleic acid amplification tests, as well 75 as clinical assessment including case diagnosis and symptom tracking. To assess viral concen-76 tration, RT-qPCR tests were conducted when possible, using anterior nares and oropharyngeal 77 swabs collected by a trained professional and combined into a single viral transport media. Cycle 78 threshold (Ct) values were obtained from the Roche cobas target 1 assay. Ct values were con-79 verted to genome equivalents per milliliter using a standard curve.¹⁴ Data on participant age and 80 vaccination status were collected where possible. Viral lineages were assigned using whole-ge-81 nome sequencing (Supplementary Methods), when feasible. This resulted in a longitudinal da-82 taset of 424,401 SARS-CoV-2 tests with clinical COVID-19 history and demographic information 83 for 3,021 individuals. 84

85

During the data collection period, 3,346 infections were identified among the 3,021 individuals. 86 These infections reflected the timing, intensity, and lineage composition of SARS-CoV-2 trans-87 mission in the broader United States (Figure 1). Of these infections, we identified 1.989 "well-88 documented" infections that were sufficiently sampled to infer viral kinetics (Table 1), as defined 89 90 by at least one RT-qPCR test with cycle threshold (Ct) value under 32 and three tests with Ct values under 40¹¹ One individual had four total infections, and we omitted their third and fourth 91 from the analysis. Of the well-documented infections, 193 were second infections, as evidenced 92 by a previous positive test more than 30 days prior to infection or a clinical history of prior infection 93 94 (Figure 1, Supplementary Table 1).

95

Vaccination status (unvaccinated, fully vaccinated, or boosted) was assigned at the time of the
 first positive test for each infection. Full vaccination corresponded to 14 days following either the
 second dose of a Pfizer or Moderna vaccine or the first dose of a Johnson and Johnson/Janssen
 vaccine. A person was considered "boosted" 14 days after an additional Pfizer or Moderna dose
 following their initial vaccination course.

101

Estimating viral kinetic parameters. We characterized the viral kinetics of the well-documented 102 infections by fitting a hierarchical piecewise linear model to the viral concentration measurements 103 on a logarithmic scale, following previous methods.^{11,14} The model captures the viral proliferation 104 time (*i.e.*, time from first possible detection to peak), peak viral concentration, and clearance time 105 (i.e., time from peak to last possible detection) of acute SARS-CoV-2 infections. The hierarchical 106 structure allowed us to estimate population-level differences in viral kinetic parameters associated 107 with vaccination status, viral lineage, and history of a prior SARS-CoV-2 infection. We adjusted 108 the model fits by the age group of the infected individual (0-29 years, 30-49 years, and 50+ 109 years). Model parameters were fit using a Hamilton Monte Carlo algorithm implemented in R 110 111 (version 4.1.2) and Stan (version 2.21.3).

112

113 <u>Study outcomes.</u> We assessed whether Omicron BA.1/BA.2 viral kinetics differed according to 114 whether the infection was the individual's first SARS-CoV-2 infection (n = 1,241 well-documented

infections) or their second infection (n = 159 well-documented infections; **Supplementary Table**

1, group 1), stratifying by booster status and adjusting for age. Then, for the subset of individuals

with a first infection by a non-Omicron lineage (verified by whole-genome sequencing or an infec-117 tion onset prior to November 11th, 2021) and a second infection with BA.1 or BA.2 (n = 235 well-118 documented infections among 177 individuals; Supplementary Table 1, group 2), we estimated 119 (a) the difference in mean viral kinetics (proliferation time, clearance time, and peak viral load) 120 between first and second infections and (b) the difference in viral kinetics of a second BA.1/BA.2 121 infection associated with the variant category of the first infection (Alpha, Delta, or other lineages). 122 We note that individuals who underwent two infections may differ from the rest of the population 123 in terms of their exposure patterns, immunity, and/or sampling patterns. Last, using the subset of 124 individuals (n = 58; Supplementary Table 1, group 3) with two well-documented infections, we 125 assessed whether a person's relative individual-level viral kinetic features (proliferation time, 126 clearance time, or peak viral load) persisted across infections. 127

128

Statistical approach. We assessed differences in viral kinetic parameters across category subsets (*e.g.*, by presence/absence of a prior infection or by vaccination status) by subtracting the relevant posterior draws and measuring the posterior probability mass of these differences that sat above/below 0, depending on the scenario. When fewer than 5% of these differenced posterior draws sat above/below zero, we took this as evidence of a significant difference.

134

To assess relative persistence in individual-level viral kinetic attributes across infections, we 135 measured the Spearman correlation between the rank of the viral kinetic parameter in the first 136 infection and the rank of the same parameter for the same person in the second infection, relative 137 to all other infections caused by the same variant in individuals with two well-documented infec-138 tions (Supplementary Methods). We used Spearman correlation because, as a rank-based 139 measure, it is less affected by outliers and non-linear relationships between the viral kinetics in 140 the first and second infection. As a sensitivity analysis, we repeated the analysis using the more 141 common Pearson correlation (Supplementary Methods). To assess the statistical significance 142 of the correlations, we conducted permutation tests, randomly assigning first- and second-infec-143 tion viral kinetic parameters to different individuals and re-calculating the correlation. We then 144 compared the true correlation to the distribution of correlations achieved through 100,000 permu-145 tations and concluded a significant difference when the true correlation was higher than 95% of 146 the correlations obtained from permutation. 147

148

<u>Study oversight.</u> This work was approved as "research not involving human subjects" by the Yale
 Institutional Review Board (HIC protocol # 2000028599), as it involved de-identified samples. This
 work was also designated as "exempt" by the Harvard Institutional Review Board (IRB20-1407).

152

154

153 **Results.**

155 In BA.1/BA.2 infections, evidence of a previous infection correlates with faster clearance. Omicron 156 BA.1/BA.2 infections in individuals with a history of prior infection (n = 159) featured a faster mean

clearance time (4.9 days (4.5, 5.3)) than Omicron BA.1/BA.2 infections in individuals with no prior

infection history (*n* = 1,241; 7.2 days (6.8, 7.5)) (**Figure 2A–B; Supplementary Table 1, group**

1). Even in individuals who had received a booster vaccine dose. BA.1/BA.2 clearance times were 159 faster in individuals with a history of prior infection (5.1 days (4.5, 5.7)) than in those with no such 160 history (7.1 days (6.7, 7.6); Supplementary Table 2). Omicron BA.1/BA.2 clearance rates were 161 also faster in vaccine-boosted individuals with a history of prior infection (2.6 Ct/day (2.2, 3.0)) 162 than in those without (2.0 Ct/day (1.8, 2.1); Supplementary Table 2). The reduction in second-163 infection clearance time also resulted in greater symmetry between proliferation and clearance 164 times (ratio of proliferation time to clearance time: 0.7 (0.6, 0.8) for the n = 1,241 BA.1/BA.2 in-165 fections with no prior infection history vs. 0.9 (0.7, 1.0) for the n = 159 BA.1/BA.2 infections with 166 prior infection history). 167

- 168
- 169 In individuals with multiple infections, second infections were cleared faster than first infections,
- especially when there was an intervening vaccine dose. We found no significant difference in proliferation time or peak viral concentration between first infections caused by Alpha, Delta, or
- other/unspecified lineages in individuals with a later Omicron BA.1/BA.2 infection (n = 78) vs.
- other/unspecified lineages in individuals with a later Omicron BA.1/BA.2 infection (n = 78) vs. second infections caused by Omicron BA.1 or BA.2 in individuals with a previous Alpha, Delta, or
- second infections caused by Omicron BA.1 or BA.2 in individuals with a previous Alpha, Delta, or other/unspecified infection (n = 157) (**Supplementary Table 1, group 2**). However, in this group,
- clearance times were substantially faster in second infections (5.1 days (4.7, 5.7) vs. 8.8 days
- (7.8, 9.8) in first infections, **Supplementary Table 3**). Clearance rates were also substantially faster in second infections within this group (2.4 Ct/day (2.1, 2.7) vs. 1.6 Ct/day (1.3, 1.8) in first infections, **Supplementary Table 3**). Individuals in this group who had an intervening vaccine dose between their first and second infection had a somewhat faster mean second-infection viral clearance time than those without an intervening dose (5.2 days (4.5, 9.5) with an intervening
- dose; 6.2 days (4.2, 8.8) without an intervening dose), though these estimates carry substantial
- uncertainty (Figure 2C–F, Supplementary Table 3). As before, the reduction in second-infection
- clearance time also resulted in greater symmetry between proliferation and clearance times (ratio
- of proliferation time to clearance time: 0.4 (0.3, 0.6) for the n = 78 first infections vs. 0.9 (0.7, 1.1)
- 185 for the n = 157 second infections).
- 186
- 187

No evidence that the kinetics of a second infection by BA.1/BA.2 differ according to the first infection's lineage. We found no evidence the variant category of a previous infection (Alpha vs. Delta vs. other/unspecified) affected the mean viral kinetics of a later Omicron BA.1/BA.2 infection (n =157, **Supplementary Table 1 group 2; Supplementary Table 5**). That is, regardless of the lineage of the initial infection, the viral kinetics of second BA.1/BA.2 infections had similar features to one another, though not to the first infection.

194

An individual's relative clearance speed is preserved across infections. Among individuals with two well-documented infections (n = 58; **Supplementary Table 1, group 3**), the ranking of clearance times was roughly conserved across first and second infections; that is, those with a relatively short clearance time in their first infection tended to have a short clearance time in their second infection, and *vice versa* (**Figure 3**). The Spearman correlation coefficient between individual-level mean clearance times for first *vs.* second infections was 0.475 overall (p = 0.0001.

permutation test). When stratified by the variant category of the first infection, the Spearman correlation between individual-level mean clearance times for first *vs.* second infections was 0.783,

0.352, and 0.396 for Alpha, Delta, and infections with other/unspecified lineages, respectively.

- We found somewhat weaker evidence that a person's proliferation time rank was conserved
- across infections, with a Spearman correlation coefficient of 0.267 (p = 0.02, permutation test) for
- first *vs.* second infections. We did not find evidence that an individual's peak viral concentration rank was maintained across infections. These findings were robust to the choice of correlation
- statistic (Pearson *vs.* Spearman; **Supplementary Table 6**).
- 209

210 Discussion.

211

In individuals with multiple infections, second infections were cleared more quickly than first in-212 fections, especially when there was an intervening vaccine dose between the two infections. The 213 lineage of the first infection did not meaningfully affect the viral kinetics of a later BA.1/BA.2 infec-214 tion. However, one's relative speed of clearing infection persisted across infections: those with a 215 216 relatively fast clearance speed in their first infection tended to have a relatively fast clearance speed in their second infection, and vice versa, when compared to others infected with the same 217 variant. Thus, while prior infection and vaccination can modulate a person's viral kinetics in abso-218 lute terms, there may also exist some further immunological mechanism, conserved across se-219 quential infections, that determines one's strength of immune response against SARS-CoV-2 rel-220 ative to others in the population. 221

222

The mechanism underlying this persistence in clearance speed rank across subsequent infections 223 is unclear. Some possibilities include the recency of exposure to a different related coronavirus 224 (e.g., HKU1 or OC43),¹⁵ immune imprinting from early-lifetime exposure to certain coronavirus 225 lineages,¹⁶ or an inherent, genome-mediated aspect of immune response. It is also unclear 226 whether one's relative ability to clear SARS-CoV-2 infection generalizes to other coronaviruses 227 or to other pathogens. Serological studies and genome-wide association studies may help to illu-228 minate the mechanisms behind persistence in SARS-CoV-2 clearance time. Such studies would 229 be valuable for improving our basic understanding of immune response to respiratory pathogens 230 and for developing personalized clinical respiratory disease management protocols. 231

232

A consistent finding between this and other studies on SARS-CoV-2 viral kinetics is that prior 233 antigenic exposure, through infection or vaccination, tends to speed up viral clearance, and thus 234 to reduce the duration of test positivity.^{5,11,17} The duration of viral positivity has various conse-235 guences both for clinical management and for public health surveillance. For clinical manage-236 237 ment, test results should be interpreted in the context of a patient's immune history, which can modulate both the extent and expected duration of viral shedding.^{5,14} It may also be possible to 238 adjust the recommended duration of post-infection isolation based on infection history. When es-239 timating epidemic growth rates using cross-sectional RT-gPCR test results, it is critical to account 240 for immune-mediated shifts in the asymmetry between viral clearance to viral proliferation times, 241

since this asymmetry is a key component in determining whether an epidemic is growing or shrinking.⁷ We find that the difference between viral proliferation and viral clearance times decreases in second infections, which may reduce certainty in epidemic growth rates derived from cross-sectional RT-qPCR-based methods.

246

This study is limited by various factors. The cohort is predominately young, male, and healthy. 247 While we adjusted for age, comorbidities and other underlying health factors were not measured. 248 We were unable to fully disentangle the effect of both variant and first vs. second infection simul-249 taneously due to small sample sizes when the population was separated into such narrow cate-250 gories. Still, our findings are consistent with other studies showing that immunity tends to reduce 251 clearance time;^{5,11,17} thus, we expect that our findings of relatively lower peak viral load and faster 252 clearance in second infections are at least partially features of immune response and not just to 253 viral lineage alone. This study focuses primarily on individuals who were ultimately infected twice, 254 and these individuals may differ in important immunological and behavioral ways from those who 255 only underwent one infection during the study period. This underscores the need for further stud-256 257 ies that capture viral and serological kinetics in tandem.

258

In conclusion, immunity from a first SARS-CoV-2 infection affects the viral kinetics of a second 259 SARS-CoV-2 infection principally by speeding up viral clearance and thus shortening the overall 260 time of acute infection. The kinetics of a second BA.1/BA.2 infection are unaffected by the lineage 261 of the first infection. Individuals who quickly cleared their first infection also tended to quickly clear 262 their second infection, pointing towards persistence of underlying immune response across mul-263 tiple infections. These findings help guide the interpretation of quantitative SARS-CoV-2 tests 264 both clinically and for surveillance and point towards persistent individual-level immune mecha-265 nisms against SARS-CoV-2 that so far remain unexplained. 266

Table 1. Characteristics of the well-documented infections. Counts by lineage, vaccination status, age
 group, and cardinality of infection (first, second, third, or fourth) for the 1,989 well-documented infections.
 Well-documented infections are those with at least one RT-qPCR Ct < 32 and three Ct < 40 (the limit of
 detection). Infections occurred between 11th March 2020 and 28th July 2022.

Statistic	Category	Ν	%
Total		1989	100
Lineage +	Alpha	49	2.5
vaccination status at	Unvaccinated	24	1.2
time of infection	Vaccinated	4	0.2
	Unknown primary vaccination status	21	1.1
	Unboosted	22	1.1
	Boosted	0	0.0
	Unknown booster status	27	1.4
	Delta	191	9.6
	Unvaccinated	7	0.4
	Vaccinated	123	6.2
	Unknown primary vaccination status	61	3.1
	Unboosted	99	5.0
	Boosted	10	0.5
	Unknown booster status	82	4.1
	BA.1/BA.2	1400	70.4
	Unvaccinated	6	0.3
	Vaccinated	994	50.0
	Unknown primary vaccination status	400	20.1
	Unboosted	117	5.9
	Boosted	778	39.1
	Unknown booster status	507	25.5
	BA.4/BA.5	71	3.6
	Unvaccinated	0	0.0
	Vaccinated	53	2.7
	Unknown primary vaccination status	18	0.9
	Unboosted	0	0.0
	Boosted	50	2.5
	Unknown booster status	21	1.1
	Other/Unspecified	278	14.0
	Unvaccinated	98	4.9
	Vaccinated	81	4.1
	Unknown primary vaccination status	99	5.0
	Unboosted	92	4.6
	Boosted	55	2.8
	Unknown booster status	131	6.6
Age group	0-29	816	41.0
	30-49	876	44.0
	50-99	295	14.8
	Not Reported	2	0.1
Infection number	1	1796	90.3
	2	193	9.7



Figure 1. Onset times of repeat and overall infections in the dataset. (A): Histogram of first positive 281 test dates for all recorded infections in full dataset (n = 3,346). Colors in both panels correspond to the 282 SARS-CoV-2 variant category (Other/Unspecified: Black; Alpha: Blue; Delta: Red; BA.1/BA.2: Magenta), 283 where Other/Unspecified include all non-Alpha, Delta, and Omicron lineages and any samples that could 284 285 not be sequenced. (B): Date of the first positive test (points) for well-documented infections (n = 235) in individuals with an initial Alpha, Delta, or Other/Unspecified infection (n = 78 well-documented infections) 286 and a second BA.1/BA.2 infection (n = 157 well-documented infections; see also Supplementary Table 1, 287 group 2). Horizontal lines connect the points that correspond to multiple infections that belong to a single 288 person. Lines that extend off the plot range to the left indicate the absence of a well-documented (though 289 clinically confirmed) first infection, and lines that extend off the plot range to the right indicate the absence 290 291 of a well-documented (though clinically confirmed) second infection.



293



- infections. These values are repeated in grey on the lower plots (B, D, F) to facilitate comparison with the
- viral kinetics of second infections.

314 A)



Figure 3. Relative viral kinetic parameters for first vs. second SARS-CoV-2 infections. (A): Spearman 322 correlation (points) of peak viral load, proliferation time, and clearance time for first vs. second infections 323 among n = 58 individuals with two well-documented infections (Supplementary Table 1, group 3). The 324 height of the grey shaded area is proportional to the probability that the Spearman correlation would fall at 325 a particular value given no correlation between first- and second-infection parameters. (B-D): Scatter plots 326 of the normalized order statistics (points) for the peak viral concentration (B), proliferation time (C), and 327 clearance time (D) for first vs. second infections in the n = 58 individuals with two well-documented infec-328 tions. Points are colored according to the variant of the first infection (Other/None: black; Alpha: blue; Delta: 329 red); all second infections were caused by BA.1/BA.2. Dashed lines depict the best-fit linear regression to 330 the normalized order statistics when stratified by the variant of the first infection. The solid black line depicts 331 the overall best-fit linear regression to the normalized order statistics combined across all first-infection 332 333 variants. The grey regions depict the 95% confidence regions for this overall trend line. Order statistics were calculated by ranking the mean posterior values for each parameter (peak viral load, proliferation time, 334 clearance time) for each infection within a variant/cardinality group (e.g., Delta/first infection). Then, these 335 ranks were divided by the maximum rank for that variant/cardinality group, so that the normalized order 336 statistics fall between 0 and 1. 337

338 Supplementary Methods.

339

Genome sequencing and lineage alignment. Following previously described methods, RNA was 340 extracted from clinical samples and confirmed as SARS-CoV-2 positive.¹⁸ Sequencing was per-341 formed using the Illumina COVIDSeg ARTIC viral amplification primer set (V4, 384 samples, cat# 342 20065135). Library preparation was performed using the amplicon-based Illumina COVIDseq 343 Test v033 and sequenced 2×74 on Illumina NextSeq 550 following Illumina's documentation. The 344 resulting FASTQ files were processed and analyzed on Illumina BaseSpace Labs using the Illu-345 mina DRAGEN COVID Lineage Application;¹⁹ versions included were 3.5.0, 3.5.1, 3.5.2, 3.5.3, 346 and 3.5.4. The DRAGEN COVID Lineage pipeline was run with default parameters as recom-347 mended by Illumina. Lineage assignment and phylogenetics analysis were accomplished using 348 the most recent versions of Pangolin²⁰ and NextClade,²¹ respectively. 349

350

Assessing persistence in viral kinetic parameters across infections. An individual's viral kinetics 351 are expected to change substantially across subsequent infections due to the accumulation of 352 immunity through both infection and vaccination and due to differences in viral lineage, among 353 other factors. Furthermore, the impact that these factors have on viral kinetics may be non-linear 354 and individual-specific. Because of this, a naïve measurement of similarity between viral kinetic 355 parameter values in first vs. second infections is unlikely to yield valuable insights. However, more 356 information might be obtained by comparing an individual's viral kinetics against those of similar 357 individuals, in terms of variant and immune history, in first vs. second infections. This is the moti-358 vation for using the Spearman correlation for assessing associations in viral kinetic parameters 359 across subsequent infections. 360

361

To measure the Spearman correlation between first and second infections for a given viral kinetic 362 parameter, we first assigned a rank to the mean posterior value for that parameter for all individ-363 uals in an infection cardinality/variant group. That is, within each group of (a) first infections 364 caused by Alpha, (b) first infections caused by Delta, (c) first infections caused by other/unspeci-365 fied lineages, and (d) first infections caused by BA.1/BA.2, we ranked the viral kinetic parameter 366 (say, peak viral load) from least to greatest. Next, we divided the ranks by the maximum rank for 367 each group, so that the normalized ranks all fell between 0 and 1. Finally, we measured the cor-368 relation between the normalized ranks for all second vs. first all infections; this is the Spearman 369 correlation. We normalized the values so that all the cardinality/variant groups would have a sim-370 ilar scale; the Spearman correlation is unaffected by such multiplicative normalizations. As a re-371 sult, individuals with a normalized order statistic close to 1 had a large estimated value for the 372 viral kinetic parameter relative to others in their cardinality/variant group, while individuals with a 373 normalized order statistic close to 0 had a small estimated value for the viral kinetic parameter 374 relative to others in their cardinality/variant group. 375

376

To assess robustness to this approach, we also measured the Spearman correlations fully strat-377 ified by the variant category of the first infection. That is, for each viral kinetic parameter, we 378 measured the Spearman correlation three times, once for individuals whose first infection was 379 caused by Alpha, once for individuals whose first infection was caused by Delta, and one for 380 individuals whose first infection was caused by an other/unspecified lineage. Then, when normal-381 izing the BA.1/BA.2 order statistics, we maintained these groups, so that the second infection for 382 an individuals who was previously infected by Alpha was only compared against other individuals 383 who were also previously infected by Alpha. This stands in contrast to the previous approach, for 384 which (a) all BA.1/BA.2 infections were ranked against one another regardless of the lineage of 385

the first infection and (b) once the order statistics were calculated for each infection cardinality/variant group, all first infections were combined to generate a single regression. These values

- are reported in **Supplementary Table 7**.
- 389

³⁹⁰ We further assessed the sensitivity of this approach by calculating the standard Pearson correla-

- tion between the viral kinetic parameters, using the raw estimated mean posterior values for each
- ³⁹² person in their first and second infections (**Supplementary Figure 1, Supplementary Table 6**).
- As expected, these relationships appear to be more subject to biases due to outlying trajectories, but the general trends are the same: those with a relatively long clearance time in their first infec-
- but the general trends are the same: those with a relatively long clearance time in their first infection tended to have a long clearance time in their second infection, and *vice versa*, as measured
- by a positive Pearson correlation between clearance times in first *vs.* second infections.

397 Supplementary Table 1. Summary of well-documented infections by variant and lineage of any preceding/following infection. Counts of well-documented infections by infection cardinality (first vs. second), 398 variant category (Alpha, Delta, BA./BA.2, BA.4/BA.5, Other/Unspecified), and the variant category of any 399 preceding or following infection. The main results in this manuscript reflect a comparison between (1) 400 BA.1/BA.2 first infections (n = 1241) vs. BA.1/BA.2 second infections (n = 159), (2) Alpha/Delta/Other/Un-401 specified first infections that were followed by any BA.1/BA.2 infection (n = 78) vs. BA.1/BA.2 infections that 402 were preceded by any Alpha/Delta/Other/Unspecified infection (n = 157), and (3) Alpha/Delta/Other/Un-403 specified first infections that were followed by a well-documented BA.1/BA.2 infection (n = 58) vs. BA.1/BA.2 404 infections that were preceded by a well-documented Alpha/Delta/Other/Unspecified infection (n = 58). 405 Darker text indicates groups that are compared directly in the analyses described in the main results. Ar-406 407 rows connect the groups that are compared, with filled-in arrowheads denoting the "reference group" (first infections) and open arrowheads denoting the "comparison group" (second infections). 408

Infection number	N	Variant	N	Variant category of any preceding/following infection (well-documented or clinically confirmed)	N	Variant category of any preceding/following well-documented infection	N
First	1796	Other/	255	Followed by Alpha/Delta/Other/Unspecified	6	Followed by Alpha/Delta/Other/Unspecified	2
		Unspecified		Followed by BA.1/BA.2	46	Followed by BA.1/BA.2	33
		Alpha	48	Followed by Alpha/Delta/Other/Unspecified	3	Followed by Alpha/Delta/Other/Unspecified	0
				→ Followed by BA.1/BA.2	14	→ Followed by BA.1/BA.2	12
		Delta	191	Followed by Alpha/Delta/Other/Unspecified	9	Followed by Alpha/Delta/Other/Unspecified	3
				→ Followed by BA.1/BA.2	18	→ Followed by BA.1/BA.2	13
	Г	→ BA.1/BA.2	1241	Followed by Alpha/Delta/Other/Unspecified	11	Followed by Alpha/Delta/Other/Unspecified	1
				Followed by BA.1/BA.2	13	Followed by BA.1/BA.2	2
		BA.4/BA.5	61	Followed by Alpha/Delta/Other/Unspecified	0	Followed by Alpha/Delta/Other/Unspecified	0
	(1)		,	Followed by BA.1/BA.2	0	Followed by BA.1/BA.2	0
Second	193	Other/	23	Preceded by Alpha/Delta/Other/Unspecified	22	Preceded by Alpha/Delta/Other/Unspecified	5
		Unspecified		Preceded by BA.1/BA.2	1	Preceded by BA.1/BA.2	1
		Alpha	1	Preceded by Alpha/Delta/Other/Unspecified	1	Preceded by Alpha/Delta/Other/Unspecified	0
				Preceded by BA.1/BA.2	0	Preceded by BA.1/BA.2	0
		Delta	0	Preceded by Alpha/Delta/Other/Unspecified	0	Preceded by Alpha/Delta/Other/Unspecified	0
				Preceded by BA.1/BA.2	0	Preceded by BA.1/BA.2	0
	L	→ BA.1/BA.2	159	> Preceded by Alpha/Delta/Other/Unspecified	157	> Preceded by Alpha/Delta/Other/Unspecified	58
				Preceded by BA.1/BA.2	2	Preceded by BA.1/BA.2	2
		BA.5/BA.5	10	Preceded by Alpha/Delta/Other/Unspecified	5	Preceded by Alpha/Delta/Other/Unspecified	2
				Preceded by BA.1/BA.2	5	Preceded by BA.1/BA.2	3

- Supplementary Table 2. Viral kinetic parameters for BA.1/BA.2 infections, stratified by infection cardinality (first *vs.* second) and booster status and adjusted by age group.

Viral kinetic parameter	Category	Value
Peak viral concentration	First infection, unboosted	25.8 (24.8, 26.7)
(Ct)	First infection, boosted	25.9 (25.3, 26.5)
	Second infection, unboosted	26.7 (25.0, 28.2)
	Second infection, boosted	27.0 (25.9, 28.0)
Peak viral concentration	First infection, unboosted	6.6 (6.3, 6.9)
(GE/ml)	First infection, boosted	6.6 (6.4, 6.7)
	Second infection, unboosted	6.4 (5.9, 6.8)
	Second infection, boosted	6.3 (6.0, 6.6)
Proliferation time (days)	First infection, unboosted	4.4 (3.8, 5.2)
	First infection, boosted	5.2 (4.7, 5.9)
	Second infection, unboosted	3.6 (2.7, 4.7)
	Second infection, boosted	4.6 (3.7, 5.7)
Clearance time (days)	First infection, unboosted	6.0 (5.5, 6.6)
	First infection, boosted	7.1 (6.7, 7.6)
	Second infection, unboosted	4.5 (3.8, 5.3)
	Second infection, boosted	5.1 (4.5, 5.7)
Proliferation rate (Ct/day)	First infection, unboosted	3.2 (2.7, 3.8)
	First infection, boosted	2.7 (2.4, 3.1)
	Second infection, unboosted	3.8 (2.7, 5.1)
	Second infection, boosted	2.9 (2.2, 3.6)
Clearance rate (Ct/day)	First infection, unboosted	2.4 (2.1, 2.6)
	First infection, boosted	2.0 (1.8, 2.1)
	Second infection, unboosted	3.0 (2.4, 3.6)
	Second infection, boosted	2.6 (2.2, 3.0)

- Supplementary Table 3. Viral kinetic parameters for first *vs.* second infections in individuals with multiple infections, stratified by vaccination status.

Viral kinetic parameter	Category	Value
Peak viral concentration	First infection, overall	26.3 (25.1, 27.5)
(Ct)	First Infection, unvaccinated	26.7 (25.1, 28.2)
	First infection, vaccinated	27.0 (24.3, 29.4)
	Second infection, overall	27.6 (26.8, 28.5)
	Second Infection, no intervening dose	28.6 (24.6, 31.6)
	Second infection, intervening dose	27.9 (26.6, 29.1)
Peak viral concentration	First infection, overall	6.4 (6.1, 6.8)
(GE/ml)	First Infection, unvaccinated	6.3 (5.9, 6.8)
	First infection, vaccinated	6.3 (5.6, 7.0)
	Second infection, overall	6.1 (5.8, 6.3)
	Second Infection, no intervening dose	5.8 (5.0, 6.9)
	Second infection, intervening dose	6.0 (5.7, 6.4)
Proliferation time (days)	First infection, overall	3.8 (3.2, 4.6)
	First Infection, unvaccinated	4.1 (3.3, 5.1)
	First infection, vaccinated	3.7 (2.4, 5.3)
	Second infection, overall	4.4 (3.7, 5.2)
	Second Infection, no intervening dose	4.0 (2.4, 6.1)
	Second infection, intervening dose	4.5 (3.6, 5.6)
Clearance time (days)	First infection, overall	8.8 (7.8, 9.8)
	First Infection, unvaccinated	8.7 (7.7, 10.0)
	First infection, vaccinated	8.4 (6.5, 10.4)
	Second infection, overall	5.1 (4.7, 5.7)
	Second Infection, no intervening dose	6.2 (4.2, 8.8)
	Second infection, intervening dose	5.2 (4.5, 5.9)
Proliferation rate (Ct/day)	First infection, overall	3.6 (2.9, 4.4)
	First Infection, unvaccinated	3.3 (2.5, 4.1)
	First infection, vaccinated	3.7 (2.3, 5.7)
	Second infection, overall	2.8 (2.3, 3.4)
	Second Infection, no intervening dose	3.0 (1.7, 5.3)
	Second infection, intervening dose	2.7 (2.1, 3.5)
Clearance rate (Ct/day)	First infection, overall	1.6 (1.3, 1.8)
	First Infection, unvaccinated	1.5 (1.3, 1.8)
	First infection, vaccinated	1.6 (1.2, 2.2)
	Second infection, overall	2.4 (2.1, 2.7)
	Second Infection, no intervening dose	1.9 (1.1, 3.0)
	Second infection, intervening dose	2.3 (2.0, 2.8)

419 Supplementary Table 4. Viral kinetic parameters by variant.

Viral kinetic parameter	Category	Value
Peak viral concentration	Other/None	26.7 (25.2, 28.0)
(Ct)	Alpha	27.2 (24.7, 29.5)
	Delta	24.4 (21.8, 26.7)
	BA.1/BA.2	27.5 (26.6, 28.4)
Peak viral concentration	Other/None	6.3 (6.0, 6.7)
(GE/ml)	Alpha	6.2 (5.6, 6.9)
	Delta	7.0 (6.3, 7.7)
	BA.1/BA.2	6.1 (5.9, 6.4)
Proliferation time (days)	Other/None	4.0 (3.3, 4.9)
	Alpha	3.6 (2.6, 5.0)
	Delta	3.4 (2.3, 4.6)
	BA.1/BA.2	4.4 (3.7, 5.2)
Clearance time (days)	Other/None	9.1 (8.1, 10.3)
	Alpha	9.0 (7.2, 11.2)
	Delta	7.8 (6.3, 9.5)
	BA.1/BA.2	5.1 (4.6, 5.7)
Proliferation rate (Ct/day)	Other/None	3.3 (2.6, 4.1)
	Alpha	3.6 (2.4, 5.2)
	Delta	4.8 (3.2, 7.0)
	BA.1/BA.2	2.9 (2.3, 3.5)
Clearance rate (Ct/day)	Other/None	1.5 (1.2, 1.7)
	Alpha	1.4 (1.1, 1.9)
	Delta	2.0 (1.6, 2.6)
	BA.1/BA.2	2.4 (2.1, 2.8)

- Supplementary Table 5. Viral kinetic parameters for second infections in individuals with multiple infections, stratified by the variant of the first infection.

Category	Value
Other/None	27.3 (26.3, 28.2)
Alpha	27.2 (25.1, 29.3)
Delta	27.5 (25.3, 29.2)
Other/None	6.2 (5.9, 6.5)
Alpha	6.2 (5.6, 6.8)
Delta	6.1 (5.6, 6.7)
Other/None	4.4 (3.7, 5.2)
Alpha	4.6 (3.3, 6.3)
Delta	4.8 (3.5, 6.6)
Other/None	5.0 (4.4, 5.6)
Alpha	5.2 (4.1, 6.6)
Delta	4.9 (3.8, 6.2)
Other/None	2.9 (2.4, 3.5)
Alpha	2.9 (1.9, 4.1)
Delta	2.7 (1.8, 3.8)
Other/None	2.6 (2.2, 2.9)
Alpha	2.5 (1.8, 3.3)
Delta	2.6 (1.9, 3.5)
	Category Other/None Alpha Delta Other/None Alpha Delta Other/None Alpha Delta Other/None Alpha Delta Other/None Alpha Delta Other/None Alpha Delta

Supplementary Table 6. Correlation between viral kinetic parameters in first *vs.* second infections in individuals with two well-documented infections. Significance was calculated using a permutation test, with the *p*-value representing the proportion of draws that exceeded the calculated significance value

under the assumption of no association in viral kinetic parameters between the first and second infection.

Bold values indicate significance at the p = 0.05 level.

432

Viral kinetic parameter	Correlation statistic	Value	Significance (<i>p</i>)
Peak viral concentration	Spearman	0.0799	0.278
(Ct)	Pearson	0.128	0.172
Proliferation time (days)	Spearman	0.267	0.0206
	Pearson	0.242	0.0396
Clearance time (days)	Spearman	0.475	0.0001
	Pearson	0.336	0.0081

Supplementary Table 7. Correlation between viral kinetic parameters in first vs. second infections in individuals with two well-documented infections, stratified by the lineage of the first infection. Significance was calculated using a permutation test, with the *p*-value representing the proportion of draws that exceeded the calculated significance value under the assumption of no association in viral kinetic pa-rameters between the first and second infection. Bold values indicate significance at the p = 0.05 level.

Viral kinetic parameter	Correlation statistic	First infection lineage	Value	Significance (<i>p</i>)
Peak viral concentration	Spearman	Alpha	-0.308	0.828
(Ct)		Delta	0.330	0.132
		Other/Unspecified	0.0675	0.346
	Pearson	Alpha	-0.299	0.828
		Delta	0.416	0.0717
		Other/Unspecified	0.0627	0.357
Proliferation time (days)	Spearman	Alpha	0.245	0.218
		Delta	0.418	0.074
		Other/Unspecified	0.180	0.156
	Pearson	Alpha	0.309	0.166
		Delta	0.462	0.0857
		Other/Unspecified	0.310	0.0241
Clearance time (days)	Spearman	Alpha	0.783	0.0019
		Delta	0.352	0.114
		Other/Unspecified	0.396	0.0121
	Pearson	Alpha	0.684	0.0054
		Delta	0.486	0.0525
		Other/Unspecified	0.233	0.108

Supplementary Figure 1. Relative viral kinetic parameters for first vs. second SARS-CoV-2 infec-442 tions. (A-C): Scatter plots of the raw individual-level mean posterior viral kinetic parameter values (points) 443 for the peak viral concentration (A), proliferation time (B), and clearance time (C) for first vs. second infec-444tions in individuals with two well-documented infections. Points are colored according to the variant of the 445 first infection (Other/None: black; Alpha: blue; Delta: red); all second infections were caused by BA.1/BA.2. 446 Dashed lines depict the best-fit linear regression to the parameter values when stratified by the variant of 447 the first infection. The solid black line depicts the overall best-fit linear regression to the mean posterior 448 parameter values combined across all first-infection variants. The grey regions depict the 95% confidence 449 regions for this overall trend line. 450

451



Acknowledgements. The authors acknowledge Radhika Samant and Sarah Connolly for assistance with data curation.

- 456
- 457

Funding. Supported in part by CDC contract #200-2016-91779, a sponsored research agree-

- ment to Yale University from the National Basketball Association contract #21-003529, and the
- 460 National Basketball Players Association. Disclaimer: The findings, conclusions, and views ex-
- pressed are those of the author(s) and do not necessarily represent the official position of the
- ⁴⁶² Centers for Disease Control and Prevention (CDC).

463

464

Data and code availability.

- All data and code needed to reproduce the findings in this manuscript may be accessed in the
- 467 following repository: <u>https://github.com/skissler/Ct_SequentialInfections</u>

468 **References.**

469

470
 1. Klaassen, F. *et al.* Changes in population immunity against infection and severe disease from SARS 471
 472 CoV-2 Omicron variants in the United States between December 2021 and November 2022. *Medrxiv* 472 2022.11.19.22282525 (2022) doi:10.1101/2022.11.19.22282525.

- 473 2. Kojima, N., Shrestha, N. K. & Klausner, J. D. A Systematic Review of the Protective Effect of Prior
 474 SARS-CoV-2 Infection on Repeat Infection. *Eval Health Prof* 44, 327–332 (2021).
- 3. Abu-Raddad, L. J., Chemaitelly, H., Bertollini, R. & Epidemiology, N. S. G. for C.-19. Severity of SARSCoV-2 Reinfections as Compared with Primary Infections. *New Engl J Med* 385, 2487–2489 (2021).
- 477 4. Bowe, B., Xie, Y. & Al-Aly, Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
 478 *Nat Med* 28, 2398–2405 (2022).
- 5. Hay, J. A. *et al.* Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. *Elife* 11, e81849 (2022).

6. Tom, M. R. & Mina, M. J. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. *Clin Infect Dis* 71, ciaa619- (2020).

- 7. Hay, J. A. *et al.* Estimating epidemiologic dynamics from cross-sectional viral load distributions. *Science* 373, eabh0635 (2021).
- 485 8. Ke, R. *et al.* Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. *Nat Microbiol* 7, 640–652 (2022).
- 9. Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. *Nat Rev Microbiol* 1–
 15 (2022) doi:10.1038/s41579-022-00822-w.
- 489 10. Wyllie, A. L. *et al.* Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *New* 490 *Engl J Med* 383, 1283–1286 (2020).
- 11. Kissler, S. M. *et al.* Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons. *New Engl J Med* 385, 2489–2491 (2021).
- 12. Kissler, S. M., Fauver, J. R., Mack, C. & others. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. *England Journal of ...* (2021).
- 13. Cevik, M. *et al.* SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe* 2, e13–e22 (2021).
- 497 14. Kissler, S. M. *et al.* Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and
 498 public health strategies. *PLoS Biol.* 19, e3001333 (2021).
- 15. Yamaguchi, T., Shinagawa, T., Kobata, H. & Nakagawa, H. Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19. *Int J Infect Dis* 109, 261–268 (2021).
- 16. Aydillo, T. *et al.* Immunological imprinting of the antibody response in COVID-19 patients. *Nat Commun* 12, 3781 (2021).

- 17. Singanayagam, A. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta
- 504 (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, co-505 hort study. *Lancet Infect Dis* 22, 183–195 (2022).
- 18. Vogels, C. B. F. *et al.* Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. *Plos Biol* 19, e3001236 (2021).
- 19. BaseSpace Labs. DRAGEN COVID lineage. (2021).
- 509 20. Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epi-510 demiology. *Nat Microbiol* 5, 1403–1407 (2020).
- 511 21. Aksamentov, I., Roemer, C., Hodcroft, E. & Neher, R. Nextclade: clade assignment, mutation calling 512 and quality control for viral genomes. *J Open Source Softw* 6, 3773 (2021).
- 513